Komal Jhaveri, Carey K Anders, Aditya Bardia, Manali Bhave, A Jo Chien, Ian Krop, Tiffany A Traina, Yara Abdou, Reva Basho, Alison K Conlin, Francisco J Esteva, Kevin R Fox, Vijayakrishna Gadi, Peter A Kaufman, Anya Litvak, Cynthia X Ma, Eleftherios P Mamounas, Heather McArthur, Kelly McCann, Zahi Mitri, Rebecca Shatsky, Melinda Telli, Mylin A Torres, Kevin Kalinsky
{"title":"专家观点的争议和关键知识差距在乳腺癌管理:第一次弥合差距在乳腺癌研讨会的会议记录。","authors":"Komal Jhaveri, Carey K Anders, Aditya Bardia, Manali Bhave, A Jo Chien, Ian Krop, Tiffany A Traina, Yara Abdou, Reva Basho, Alison K Conlin, Francisco J Esteva, Kevin R Fox, Vijayakrishna Gadi, Peter A Kaufman, Anya Litvak, Cynthia X Ma, Eleftherios P Mamounas, Heather McArthur, Kelly McCann, Zahi Mitri, Rebecca Shatsky, Melinda Telli, Mylin A Torres, Kevin Kalinsky","doi":"10.1016/j.clbc.2025.04.007","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer is the most common type of cancer for women in the United States and accounts for nearly 25% of all cancers and 16% of cancer deaths worldwide. New treatment options continue to emerge offering improved management options for patients with breast cancer. However, as these new treatments become available, clinicians are left with many questions regarding how to best utilize these treatments and improve outcomes for patients with breast cancer.</p><p><strong>Materials and method: </strong>The Bridging the Gaps in Breast Cancer panel was assembled to address challenges in the management of breast cancer. Bridging the Gaps in Breast Cancer co-chairs and session moderators identified areas of controversy and uncertainty in breast cancer management and were responsible for organizing the presentations and discussion with the expert panel of faculty throughout the meeting.</p><p><strong>Results: </strong>The Bridging the Gaps in Breast Cancer panel discussions are presented. Key critical knowledge gaps surrounding the evolving breast cancer treatment landscape identified include how to identify which patients will benefit the most from therapeutic intervention, the mechanism of resistance to newly approved therapies, which therapies may be safely omitted from a treatment regimen without harm to the patient, and the most important metric(s) in defining successful treatment in various stages and subtypes of breast cancer.</p><p><strong>Conclusions: </strong>The treatment armamentarium for the management of breast cancer continues to grow and evolve. With those new treatment options, new questions continue to arise for clinicians. Future studies are needed to address these critical gaps in knowledge about how to best utilize treatments for improved patient outcomes.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium.\",\"authors\":\"Komal Jhaveri, Carey K Anders, Aditya Bardia, Manali Bhave, A Jo Chien, Ian Krop, Tiffany A Traina, Yara Abdou, Reva Basho, Alison K Conlin, Francisco J Esteva, Kevin R Fox, Vijayakrishna Gadi, Peter A Kaufman, Anya Litvak, Cynthia X Ma, Eleftherios P Mamounas, Heather McArthur, Kelly McCann, Zahi Mitri, Rebecca Shatsky, Melinda Telli, Mylin A Torres, Kevin Kalinsky\",\"doi\":\"10.1016/j.clbc.2025.04.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Breast cancer is the most common type of cancer for women in the United States and accounts for nearly 25% of all cancers and 16% of cancer deaths worldwide. New treatment options continue to emerge offering improved management options for patients with breast cancer. However, as these new treatments become available, clinicians are left with many questions regarding how to best utilize these treatments and improve outcomes for patients with breast cancer.</p><p><strong>Materials and method: </strong>The Bridging the Gaps in Breast Cancer panel was assembled to address challenges in the management of breast cancer. Bridging the Gaps in Breast Cancer co-chairs and session moderators identified areas of controversy and uncertainty in breast cancer management and were responsible for organizing the presentations and discussion with the expert panel of faculty throughout the meeting.</p><p><strong>Results: </strong>The Bridging the Gaps in Breast Cancer panel discussions are presented. Key critical knowledge gaps surrounding the evolving breast cancer treatment landscape identified include how to identify which patients will benefit the most from therapeutic intervention, the mechanism of resistance to newly approved therapies, which therapies may be safely omitted from a treatment regimen without harm to the patient, and the most important metric(s) in defining successful treatment in various stages and subtypes of breast cancer.</p><p><strong>Conclusions: </strong>The treatment armamentarium for the management of breast cancer continues to grow and evolve. With those new treatment options, new questions continue to arise for clinicians. Future studies are needed to address these critical gaps in knowledge about how to best utilize treatments for improved patient outcomes.</p>\",\"PeriodicalId\":10197,\"journal\":{\"name\":\"Clinical breast cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-04-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical breast cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.clbc.2025.04.007\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical breast cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clbc.2025.04.007","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium.
Purpose: Breast cancer is the most common type of cancer for women in the United States and accounts for nearly 25% of all cancers and 16% of cancer deaths worldwide. New treatment options continue to emerge offering improved management options for patients with breast cancer. However, as these new treatments become available, clinicians are left with many questions regarding how to best utilize these treatments and improve outcomes for patients with breast cancer.
Materials and method: The Bridging the Gaps in Breast Cancer panel was assembled to address challenges in the management of breast cancer. Bridging the Gaps in Breast Cancer co-chairs and session moderators identified areas of controversy and uncertainty in breast cancer management and were responsible for organizing the presentations and discussion with the expert panel of faculty throughout the meeting.
Results: The Bridging the Gaps in Breast Cancer panel discussions are presented. Key critical knowledge gaps surrounding the evolving breast cancer treatment landscape identified include how to identify which patients will benefit the most from therapeutic intervention, the mechanism of resistance to newly approved therapies, which therapies may be safely omitted from a treatment regimen without harm to the patient, and the most important metric(s) in defining successful treatment in various stages and subtypes of breast cancer.
Conclusions: The treatment armamentarium for the management of breast cancer continues to grow and evolve. With those new treatment options, new questions continue to arise for clinicians. Future studies are needed to address these critical gaps in knowledge about how to best utilize treatments for improved patient outcomes.
期刊介绍:
Clinical Breast Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of breast cancer. Clinical Breast Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of breast cancer. The main emphasis is on recent scientific developments in all areas related to breast cancer. Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.